YouSaid · the spoken record

Thomas Schinecker

lines on the record
12
first
2024-11-22
most recent
2024-11-22
sittings or episodes
1
sources
podcast

Every line below is reproduced as it was said and linked to the record it came from. Nothing here is summarised or generated. Directory · Search · Corrections

  1. “So, I've been with Roche for now 21 years. And I love this company. I love the culture in this company. And I love the purpose of our company. When I talk to some of our researchers and medical doctors, when we run a clinical trial that sometimes takes three to four years in the phase three, and then the day when they see the results and they see that the result is positive and what impact they can have on patients' lives, you have people that have tears in their eyes because they see the kind of impact they can have.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  2. “with one medicine that you couldn't with the other nine that failed. And you only have a short period of time. You only have around 10 years and in some parts of the world this time is shortening even. 10 years to earn back the money. The benefit to society is of course already during these 10 years when you have launched this medicine. But the benefit to society goes way beyond. If you look at just the medicines that we have launched in our history now 44 medicines are now on the WHO list of essential medicines like antibiotics like valium, a number of other cancer medicines, etc. Now if the innovation didn't happen before because there were no incentives for innovation then these medicines Would not be as widely available as there today.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  3. “Well, if you look at pricing, you also have to look at the model of how As I mentioned, you have in pharma a cycle of about 13 years to develop a new medicine. And you have a risk profile where only one out of 10 medicines make it. So you actually have to earn the money back.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  4. “I wouldn't say that at this stage. I would say if you look at Around the globe, US, Europe, China, and Japan are where most of the innovation is coming from. US is clearly, I think, still in the leadership position, but China is catching up very quickly.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  5. “So we've done a couple of licensing deals from biotechs where we licensed in a number of molecules. And I have to say, the science is great.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  6. “Start the clinical trial, that's a year of lost time, a year of time where we cannot save a number of patients' lives if this medicine makes it. So I think Europe really needs to work on the bureaucracy piece as well.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  7. “The US is doing particularly well is that they have a much better environment for startups. So there is a much better access to venture capital. And with that, you have a lot of people actually moving to the US. So they have a lot of talent going to the US. And you see a lot of the innovation, which is translated from academia into these biotechs than actually happening more in the US and probably also China now than, for example, in Europe. So I think Europe has to get that right. The second piece that Europe has to get right is they have to reduce the amount of bureaucracy. If you look at clinical trials, et cetera, these are done in countries where you have less bureaucracy. If it takes you a year from the time you apply for clinical trial to being able to”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  8. “So it's very hard to treat diseases that happen in the brain. And why is that? Well, we have this blood brain barrier. And this blood brain barrier is there to protect our brain from viruses, from bacteria, from other things that could go into the brain and could damage our brain. And with this brain shuttle, which is a protein attached to the antibody, we can actually transport the antibody much more easily into the brain. And with that, we can treat diseases that otherwise could not be treated as effectively. In fact, we have a very promising Alzheimer medicine in our pipeline. And this antibody actually uses exactly this technology. And we hope to launch that by 28-29 time frame because then we can really tackle one of the biggest problems in healthcare today.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  9. “If you look at the last 10 years or 15 years even, we've launched about two new medicines every year. And this is quite a feat. If you look at the fact that to develop a new medicine, it takes on average around 13 years. And from the beginning of development all the way to the launch of a medicine, only about one out of 10 makes it. Now this is not a Roche specific number. This is just an industry number. So launching two every year is quite a feat. And that's the rate we want to continue. And if you continue that rate, we'll launch 20 medicines also in this decade. Now in our pipeline, we have many, many more potential medicines, but there's always nutrition. And so you have to work on many things to get just two out of the door at the end.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  10. “Antibodies and target them much more precisely at different diseases, including cancer. And I think cancer immunotherapies are a great example of that, where you can actually activate the own immune system to fight the cancer. And I think we'll go more in that direction as well. One topic we're working on is the personalized cancer vaccine. So really on how you can even more enhance your own immune system to fight off the cancer. So there are a number of steps that have been happening. And on the other hand, I think there's a lot of innovation that can still happen. And a long way to go to really eradicate cancer.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  11. “On the oncology side, I think one of the major breakthroughs was clearly the understanding of our genome. If you look back in 2003, it costs billions to sequence one genome. It took, I think, more than 10 years to sequence a single genome. Now you can do that within just days, and it costs you hundreds of Swiss francs or dollars, whatever currency you're looking into. So really understanding the genome was a real breakthrough. And with that, you could understand better the drivers of what actually drives cancer, certain oncogenes, et cetera. And with that, you can target much more precisely the root cause of cancer. Then I think the other breakthrough was when we found a way on how to use antibodies, something that naturally occurs in our body, but to take the”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source

  12. “I think it's all in the history of that region, starting with the chemical industry and then later moving into the pharma part of the industry. So I think it's all basically in the history of that region and located in the center of Europe, it's actually quite ideally located. In addition, it also has an ecosystem in terms of good universities, good educational system in general. And I think this really attracts a lot of people around the world, really talented people and can drive the innovation.”

    2024-11-22 · In Good Company with Nicolai Tangen · HIGHLIGHTS: Thomas Schinecker - CEO of Roche · IDENTIFIED FROM THE TRANSCRIPT · source